Exciting Announcement from PetVivo Holdings, Inc.
MINNEAPOLIS, MN – PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) is thrilled to announce a conference call scheduled for November 14, 2025, at 5:00 p.m. Eastern time. This event will provide valuable insights into the company's fiscal second-quarter results for the period ending September 30, 2025. Prior to the call, pertinent financial information will be released.
Details of the Conference Call
During this conference call, PetVivo’s management will present key results and subsequently engage with participants in a lively question-and-answer segment. Participants can dial in using the toll-free number (+1 669 444 9171) along with the conference ID (87234562707) and passcode (396948) to join the call. Remember, this call is an excellent opportunity for stakeholders to understand the company’s performance and future plans.
Webcast Availability
A webcast of the conference call will be accessible both live and in replay. Interested participants can find it on the Investors section of the official PetVivo website. The link will remain available for those who wish to revisit the discussion.
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. stands out as a pioneering biomedical device company focused on developing and marketing innovative medical solutions for companion animals. With its wholly-owned subsidiary PetVivo Animal Health, Inc., the company has positioned itself successfully in the market with a strategy that emphasizes leveraging human medical therapies specifically catered to animal health.
Innovative Product Pipeline
PetVivo’s commitment to animal health stems from a robust product pipeline that includes its renowned products SPRYNG™ and PrecisePRP™. SPRYNG™ incorporates advanced OsteoCushion™ technology, providing effective management for joint-related issues, including lameness and osteoarthritis, in equines and companion animals such as dogs and cats. On the other hand, PrecisePRP™ is a groundbreaking off-the-shelf platelet-rich plasma product intended for veterinary use.
Strategic Vision and Future Developments
With an extensive portfolio of patents and trade secrets, PetVivo is uniquely positioned to deliver high-quality therapeutic solutions while assuring rapid market entry ahead of traditional pharmaceuticals. This agile approach not only optimizes development timelines but aligns with the company’s goal of effectively addressing urgent health concerns in animals.
Stock Performance and Market Presence
As PetVivo continues to innovate, their stock performance on platforms such as OTCQX reflects the growing interest in their novel treatments. Maintaining investor confidence is paramount for PetVivo, and they are actively committed to demonstrating growth through strategic partnerships and product expansions.
Connecting with PetVivo Holdings, Inc.
If you have any inquiries or wish to connect further, please reach out to John Lai, CEO of PetVivo Holdings, Inc. You can contact him through the official email link provided on their website or call directly at (952) 405-6216. This is an excellent opportunity for investors and interested parties to engage and learn more about the company.
Frequently Asked Questions
What is the date and time of the upcoming PetVivo conference call?
The conference call is set for November 14, 2025, at 5:00 p.m. Eastern time.
How can I listen to the conference call?
Participants can listen by dialing +1 669 444 9171 and entering the conference ID 87234562707 along with the passcode 396948.
What products is PetVivo known for?
PetVivo is recognized for its innovative products such as SPRYNG™ with OsteoCushion™ technology and PrecisePRP™, both designed to address various health conditions in animals.
How does PetVivo plan to leverage human therapies for animals?
The company aims to efficiently translate human medical advancements into veterinary applications, ensuring accessibility to safe and effective treatments quickly.
Where can I find more information about PetVivo?
More details about PetVivo and its products can be accessed on their official website, particularly in the Investors section.
